辛伐他汀对慢性肺源性心脏病中肺动脉高压的影响  

Effect of simvastatin on pulmonary hypertension in chronic pulmonary heart disease

作　　者：邹国亮[1] 陈波[2] 邱英梅[1] 邓爱花[1] 

机构地区：[1]江西省胸科医院,江西南昌330006 [2]南昌大学医学院,江西南昌330006

出　　处：《中国医院药学杂志》2009年第8期657-659,共3页Chinese Journal of Hospital Pharmacy

摘　　要：目的:探讨辛伐他汀对慢性肺源性心脏病(肺心病)肺动脉高压的影响及其机制。方法:将60例肺心病慢性缓解期患者随机分为对照组(30例)和治疗组(30例),选取同期进行体检的健康人30例作为正常组。对照组给予抗感染、吸氧等一般常规治疗,治疗组在常规治疗的基础上加用辛伐他汀,测定治疗前后的三尖瓣区最大反流速度,计算收缩期肺动脉压(PAPs);测定治疗前后高敏感C反应蛋白(hs-CRP)含量的变化。结果:对照组、治疗组血清中的hs-CRP含量及PAPs治疗前明显高于正常组(P<0.01),治疗组与对照组治疗后hs-CRP,PAPs均较治疗前明显降低,治疗组降低数值大于对照治疗组(P<0.05)。结论:加用辛伐他汀治疗较常规治疗更有助于肺心病患者肺动脉高压的降低并能使hs-CRP含量的下降。辛伐他汀缓解肺动脉高压可能与抑制肺血管炎性反应有关。OBJECTIIVE To explore the effect and mechanism of simvastatin on pulmonary hypertension in chronic pulmonary heart disease. METHODS 61/patients were randomly divided into two groups. A control croup： routin trentment group;B observed group： simvastatin treated group;C normal group： 30 healthy people were picked up from people taking physical examination at the same stage. Group A were given with antiinfection,oxygen therapy and so Ono Group B were given with simvastatin treatment besides the treatment on group B. The maximal tricuspid regurgitation velocity before and after treatment were detected to evaluated systolic pulmonary artery pressure and the data of hs-CRP before and after treantment were also detected. RESULTS The datas of hs-CRP and PAPs in control group and observed group before treatment are higher than that in normal group （P〈0.01 ）. The data of hs-CRP and PAPs in observed group after treatment are higher than that in control group on the same stage （P〈0. 05）. CONCLUSION Simvastatin is helpful in decreaing the PAPs and hs-CRP The effect of decreasing PAPs may be related to the effect of inhibition of inflammation in pulmonary vessels.

关 键 词：辛伐他汀 肺心病 肺动脉高压 高敏感C反应蛋白 

分 类 号：R972[医药卫生—药品]